Pasithea Therapeutics公司宣布了其针对晚期癌症的1期研究积极中期数据。数据显示,其疗法在长期安全性与耐受性方面表现良好,并在接受过Mek/Braf抑制剂预处理的患者群体中展现出持久的临床活性。基于这些积极结果,公司已决定扩展研究方案。
Pasithea Therapeutics公司宣布了其针对晚期癌症的1期研究积极中期数据。数据显示,其疗法在长期安全性与耐受性方面表现良好,并在接受过Mek/Braf抑制剂预处理的患者群体中展现出持久的临床活性。基于这些积极结果,公司已决定扩展研究方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.